Avalo Therapeutics, Inc. (NASDAQ:AVTX) is among the best low priced stocks to get rich in 2026.
On June 12, BofA started coverage on Avalo Therapeutics, Inc. (NASDAQ:AVTX) with a Buy rating and a price target of $35
According to the firm, the company is a “cleaner, single-asset immunology story” following the positive Phase 2 data in hidradenitis suppurativa. If the company’s lead product, abdakibart, is compared with alternative drugs, the former may provide a more convenient monthly dosing schedule and greater impact on disease outcomes, the firm added. BofA views the investment case as “a differentiated IL-1β antibody in HS, a large undertreated market, and a balance sheet with runway through next major data readout into 2029e after ~$405M net proceeds.” The company’s one-year return is what catches the eye, with an impressive 183% market outperformance.
This doesn’t stop here as the company’s future looks equally promising. With a bullish stance from all 14 analysts covering the stock, Avalo Therapeutics, Inc. (NASDAQ:AVTX) has a 1-year upside potential of 195.92%. No wonder AVTX is among the best low-priced stocks to get rich in 2026.